SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
AstraZeneca PLC (AZN) trades at a trailing P/E of 30.3, forward P/E of 19.9. Trailing earnings yield is 3.30%, forward earnings yield 5.03%. PEG 0.03 (Peter Lynch undervalued ≤1.0). Graham Number is $68.74.
Criteria proven by this page:
- VALUE (29/100, Fail) — analyst consensus target implies downside from the current price ($105.50, 48.4%).
- Forward P/E 19.9 (down from trailing 30.3) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.03 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 3.30% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 5.03% as earnings recover.
- Analyst consensus target $105.50 (-48.4% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 64/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
29/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AZN
Valuation Multiples
P/E (TTM)30.3
Forward P/E19.9
PEG Ratio0.03
Forward PEG1.64
P/B Ratio6.46
P/S Ratio5.28
EV/EBITDA16.9
Per Share Data
EPS (TTM)$6.69
Forward EPS (Est.)$10.28
Book Value / Share$31.41
Revenue / Share$38.36
FCF / Share$6.61
Yields & Fair Value
Earnings Yield3.30%
Forward Earnings Yield5.03%
Dividend Yield1.56%
Graham Number$68.74
SharesGrow IV$411.20 (+101.2%)
Analyst Target$105.50 (-48.4%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
9.7 |
0.40 |
2.29 |
1.48 |
10.45% |
| 2017 |
14.5 |
-1.00 |
2.90 |
1.93 |
8.11% |
| 2018 |
22.3 |
-0.79 |
3.86 |
2.18 |
7.24% |
| 2019 |
49.2 |
-1.25 |
5.00 |
2.69 |
5.47% |
| 2020 |
20.7 |
0.15 |
4.24 |
2.49 |
5.39% |
| 2021 |
733.4 |
-7.58 |
2.09 |
2.20 |
4.69% |
| 2022 |
32.1 |
0.01 |
2.85 |
2.38 |
4.14% |
| 2023 |
17.4 |
0.22 |
2.65 |
2.26 |
4.32% |
| 2024 |
14.3 |
-0.35 |
2.47 |
1.86 |
4.59% |
| 2025 |
13.3 |
0.07 |
2.79 |
2.32 |
3.74% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$1.38 |
$23B |
$3.5B |
15.2% |
| 2017 |
$1.19 |
$22.47B |
$3B |
13.4% |
| 2018 |
$0.85 |
$22.09B |
$2.16B |
9.8% |
| 2019 |
$0.52 |
$24.38B |
$1.34B |
5.5% |
| 2020 |
$1.22 |
$26.62B |
$3.2B |
12% |
| 2021 |
$0.04 |
$37.42B |
$112M |
0.3% |
| 2022 |
$1.06 |
$44.35B |
$3.29B |
7.4% |
| 2023 |
$1.91 |
$45.81B |
$5.96B |
13% |
| 2024 |
$1.13 |
$54.07B |
$7.04B |
13% |
| 2025 |
$13.08 |
$58.74B |
$10.26B |
17.5% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$10.29 |
$10.12 – $10.59 |
$63.02B |
$61.42B – $64.06B |
8 |
| 2027 |
$11.61 |
$11.14 – $12.11 |
$67.29B |
$64.27B – $68.91B |
8 |
| 2028 |
$12.92 |
$9.58 – $14.36 |
$71.43B |
$71.4B – $71.47B |
7 |
| 2029 |
$14.39 |
$13.51 – $14.91 |
$76.44B |
$72.81B – $78.54B |
2 |
| 2030 |
$16.08 |
$15.09 – $16.66 |
$81.11B |
$77.26B – $83.34B |
5 |
